Explorative Trial to Identify the Impact of Denosumab on the Systemic Immunity and Local Immunologic Microenvironment in Postmenopausal Patients With HER2 Negative Breast Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Pharmacodynamics
- Acronyms PERIDENO
- 22 Jul 2019 Status changed from discontinued to withdrawn prior to enrolment.
- 28 Feb 2019 Status changed from not yet recruiting to discontinued.
- 24 May 2018 New trial record